Result of AGM

RNS Number : 8397D

ReNeuron Group plc

19 September 2008

 



Results of 2008 Annual General Meeting

Guildford, UK, 19 September 2008: ReNeuron Group plc (LSE: RENE) announces that all resolutions put to its shareholders at today's 2008 Annual General Meeting were passed.

Enquiries:

ReNeuron
Michael Hunt, Chief Executive Officer	Tel: [phone]

Financial Dynamics
David Yates	Tel: [phone]
Lara Mott

Collins Stewart
Adam Cowen	Tel: [phone]

About ReNeuron

ReNeuron is a leading, UK-based stem cell company. Its primary objective is the development of stem cell therapies targeting areas of significant unmet or poorly met medical need.  

ReNeuron has filed for approval to commence initial clinical studies with its lead ReN001 stem cell therapy for disabled stroke patients. There are an estimated 50 million stroke survivors worldwide, approximately one half of which are left with permanent disabilities. The annual health and social costs of caring for these patients is estimated to be in excess of £5 billion in the UK and in excess of US$50 billion in the US. In addition to its stroke programme, ReNeuron is developing stem cell therapies for a number of other conditions, including peripheral ischaemia, Type 1 diabetes and diseases of the retina.

ReNeuron has also developed a range of stem cell lines for non-therapeutic applications - its ReNcell® products for use in academic and commercial research. ReNeuron's ReNcell®CX and ReNcell®VM neural cell lines are marketed worldwide under license by US-based Millipore Corporation.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.

Data sources: UK Stroke Association; American Stroke Association

This announcement contains forward-looking statements with respect to the financial condition, results of operations and business achievements/performance of ReNeuron and certain of the plans and objectives of management of ReNeuron with respect thereto. These statements may generally, but not always, be identified by the use of words such as 'should', 'expects', 'estimates', 'believes' or similar expressions. This announcement also contains forward-looking statements attributed to certain third parties relating to their estimates regarding the growth of markets and demand for products. By their nature, forward-looking statements involve risk and uncertainty because they reflect ReNeuron's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of factors could cause ReNeuron's actual financial condition, results of operations and business achievements/performance to differ materially from the estimates made or implied in such forward-looking statements and, accordingly, reliance should not be placed on such statements.

 

END

 

 

RAGUKSKRWVRKARR